Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19.
作者信息
Piñana José Luis, Garcia-Sanz Ramon, Martino Rodrigo, Garcia-Roa María, Martin-Martin Gabriel Andrés, Risco-Gálvez Irene, Tormo Mar, Martinez-Barranco Pilar, Marcos-Corrales Sara, Calabuig Marisa, Conesa Venancio, Teruel Anabel, Ruiz-Pérez Sara, Solano Carlos, Navarro David, Cedillo Ángel, Sureda Anna
机构信息
Hematology Department and.
Fundación INCLIVA, Instituto de Investigación Sanitaria, Hospital Clínico Universitario de Valencia, Valencia, Spain.
出版信息
Blood Adv. 2022 Jan 8;6(3):848-853. doi: 10.1182/bloodadvances.2021006326.
Abstract
摘要
相似文献
1
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19.
Blood Adv. 2022 Jan 8;6(3):848-853. doi: 10.1182/bloodadvances.2021006326.
2
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.
Leuk Lymphoma. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. Epub 2021 Oct 20.
3
Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
Front Immunol. 2023 Oct 17;14:1257360. doi: 10.3389/fimmu.2023.1257360. eCollection 2023.
4
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
Microbiol Spectr. 2023 Jun 15;11(3):e0436322. doi: 10.1128/spectrum.04363-22. Epub 2023 May 10.
5
Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
Front Immunol. 2022 Aug 24;13:940562. doi: 10.3389/fimmu.2022.940562. eCollection 2022.
6
Pediatric hematology/oncology physician and nurse practitioner attitudes towards the COVID-19 vaccines: A qualitative study.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2048560. doi: 10.1080/21645515.2022.2048560. Epub 2022 Mar 28.
7
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
8
Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Obstet Gynecol. 2022 Mar 1;139(3):373-380. doi: 10.1097/AOG.0000000000004693.
9
Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2.
Intern Med J. 2022 Dec;52(12):2172-2175. doi: 10.1111/imj.15954. Epub 2022 Nov 27.
10
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
ESMO Open. 2021 Oct;6(5):100274. doi: 10.1016/j.esmoop.2021.100274. Epub 2021 Sep 8.
引用本文的文献
1
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy.
Front Oncol. 2024 Jun 19;14:1389345. doi: 10.3389/fonc.2024.1389345. eCollection 2024.
2
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706).
EJHaem. 2022 Aug 30;3(4):1201-8. doi: 10.1002/jha2.544.
3
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.
J Hematol Oncol. 2022 May 7;15(1):54. doi: 10.1186/s13045-022-01275-7.
本文引用的文献
1
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.
Cancer Cell. 2021 Aug 9;39(8):1031-1033. doi: 10.1016/j.ccell.2021.07.012. Epub 2021 Jul 22.
2
Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Transplant Cell Ther. 2021 Nov;27(11):938.e1-938.e6. doi: 10.1016/j.jtct.2021.07.008. Epub 2021 Jul 15.
3
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.
Lancet. 2021 Jul 24;398(10297):298-299. doi: 10.1016/S0140-6736(21)01594-4. Epub 2021 Jul 13.
4
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
5
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.
Br J Haematol. 2021 Oct;195(2):186-193. doi: 10.1111/bjh.17608. Epub 2021 Jul 1.
6
BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
Am J Hematol. 2021 Oct 1;96(10):1195-1203. doi: 10.1002/ajh.26284. Epub 2021 Jul 14.
7
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
8
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
Ann Intern Med. 2021 Sep;174(9):1330-1332. doi: 10.7326/L21-0282. Epub 2021 Jun 15.
9
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
10
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
Zotero 插件